Sandoz Q1 Strong Start To The Year With Biosimilars Growth

Mar, May 7th 2024

Sandoz, a Novartis spin-off, kicks off the year with a 5% revenue increase, driven by significant growth in its biosimilars division.

The former generics subsidiary of the pharmaceutical group Novartis has grown faster with its lucrative biosimilars than with “normal” generics.

Revenue between January and March climbed by 5% to 2.5 billion US dollars, as the Group announced on Tuesday. At constant exchange rates, the increase would have been 6%.

The generics business contributed 1.9 billion dollars to total sales and thus remained stable compared to the same period of the previous year.

Sandoz attributes this to factors including an exceptional cough and cold season in the first half of 2023 and the timing of new product launches in the US, which would have offset the solid volume growth.

In contrast, the smaller biosimilar division grew by 21% to 0.6 billion. This significantly stronger growth was due, among other things, to the ongoing market launch of the highly concentrated formulation of the biosimilar Hyrimoz (anti-inflammatory) and the acquisition of Cimerli.

The Basel-based company confirmed its previous target for the further course of business: net sales are expected to grow in the mid-single-digit range. The core EBITDA margin is expected to be around 20% in 2024. The future dividend payout is expected to be between 30 and 40 percent.

©Keystone/SDA

Historias relacionadas

Council of States: Cutting Asylum Credits

16 mayo 2024

Swiss Council of States committee recommends slashing the Federal Council's proposed funding for asylum centres by CHF...

Swiss Insurance Helvetia Restructuring

16 mayo 2024

Helvetia Insurance adapts its executive management and structure to boost international operations and innovation, with...

Lidl Switzerland New Head of Real Estate: Tobias Eggli

14 mayo 2024

Lidl Switzerland appoints Tobias Eggli as Head of Real Estate. With extensive experience, Eggli joins the executive...

Alcon, Swiss Pharmaceutical Firm Growth Slows

14 mayo 2024

Alcon sees a 5% increase in Q1 sales, achieving $2.44 billion with profits surging to $248 million, despite a minor...

Underground Freight Transportation in Zurich Faces Criticism

17 mayo 2024

Underground freight transport project "Cargo sous terrain" faces criticism from Zurich and other municipalities over...

Switzerland Expands Tax Transparency to Include Crypto Assets

16 mayo 2024

Switzerland extends AEOI coverage to crypto assets, enhancing financial transparency and regulatory compliance starting...

Vetropack Layoffs: Employees Demand Compensation

16 mayo 2024

Amid planned layoffs, Vetropack employees push for a social plan and the preservation of jobs at the Saint-Prex site....

Mantente en contacto

Cabe destacar

Switzerland Expands Tax Transparency to Include Crypto Assets

Cabe destacar

16 mayo 2024

Switzerland Expands Tax Transparency to Include Crypto Assets

Swiss Hells Angels Monster Trial: Drugs, Gambling, Sex Crimes & More

Cabe destacar

13 mayo 2024

Sandoz Q1 Strong Start To The Year With Biosimilars Growth

Sandoz Q1 Strong Start To The Year With Biosimilars Growth

Historias relacionadas

Mantente en contacto

Cabe destacar

Switzerland Expands Tax Transparency to Include Crypto Assets

Swiss Hells Angels Monster Trial: Drugs, Gambling, Sex Crimes & More

Enlaces rápidos